InvIOs to Highlight Oncology Pipeline Progress at JP Morgan Week 2025

invIOs GmbH, a biotechnology firm from Vienna focused on cancer therapies, will present updates during JP Morgan Week in San Francisco from January 13-16, 2025. The company will spotlight advancements in its glioblastoma treatments, involving a small molecule and a cell therapy in collaboration with Dana-Farber Cancer Institute (DFCI).

The invIOs management team will conduct one-on-one meetings to discuss their immuno-oncology pipeline and 2025 strategies. Recent developments highlight the potential of INV501, a small molecule candidate enhancing anti-tumor responses, and INV441, a TIL-based therapy with promising preclinical results. APN401, another investigational therapy, continues to show clinical promise.

INV501's preclinical success demonstrates survival benefits in glioblastoma models. Meanwhile, INV441 is set to enter Phase 1 trials in the second half of 2025. The company's ongoing efforts reflect a robust scientific approach towards novel cancer therapies.